Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses
Frontiers in Microbiology · 09.04.2026 · 17
DOI: 10.3389/fmicb.2026.1791088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 09.04.2026. Verfasst von Hyunbeen Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Disease Control and Prevention Agency.
Abstract (Originalsprache)
Influenza A viruses continuously evolve through antigenic drift and shift, reducing the effectiveness of vaccines that rely primarily on hemagglutinin (HA). Neuraminidase (NA), a surface antigen with greater sequence conservation, has gained attention as a complementary target for broader influenza vaccine design. Using computational analyses of 707 post-2009 A(H1N1)pdm09 NA sequences, we designed two NA-based mRNA vaccine constructs: NA-D1, derived from contemporary H1N1 isolates, and NA-E2, incorporating conserved features shared between H1N1 and H5N1. Mice received prime-boost immunization followed by homologous H1N1 or heterologous H5N1 challenge. Both NA-D1 and NA-E2 induced NA-specific antibody titers and conferred complete protection against homologous H1N1 infection. In contrast, protection against heterologous H5N1 was partial, consistent with lower predicted antigenic similarity between the vaccine constructs and H5N1 NA. Together, these findings demonstrate that NA-based mRNA vaccination can elicit robust homologous protection but offers limited heterologous protection efficacy. Our results support NA as an important complementary antigen for next-generation influenza vaccines and highlight the potential of computationally guided, dual-antigen (HA + NA) strategies to advance the development of broadly protective mRNA vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul, Republic of Korea.
- Division of Infectious Diseases Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Osong, Republic of Korea.
- Department of Lab Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
- Vaccine Innovation Center, Korea University College of Medicine, Seoul, Republic of Korea.
- Biosafety Center, Korea University College of Medicine, Seoul, Republic of Korea.
Förderung
- Korea Disease Control and Prevention Agency
Zitieren
APA
Kim, H., Lee, S., Cho, S., Shin, W., Lee, S., Park, S., Demirev, A. V., Lee, T., Kim, Y. J., Kim, D., Song, S. A., Jun, K. R., & Kim, J. I. (2026). Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1791088
Vancouver
Kim H, Lee S, Cho S, Shin W, Lee S, Park S, et al. Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1791088
BibTeX
@article{Kim2026,
author = {Kim, Hyunbeen and Lee, Sangyi and Cho, Seunghye and Shin, Woojin and Lee, Soyoung and Park, Sejik and Demirev, Atanas V and Lee, Taeyoung and Kim, You-Jin and Kim, Dokeun and Song, Sae Am and Jun, Kyung Ran and Kim, Jin Il},
title = {Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1791088}
}
EUVIMED